Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Wilhelm Bone

Ulrich Klar

Hans Briem

Gerhard Siemeister

Wolfgang Schwede

Andrea Rotgeri

Carsten Möller

Jens Schröder

Philip Lienau

Knut Eis

Anne Mengel

Benjamin Bader

Antje Margret Wengner

Marcus Koppitz

Simon Holton

Marion Hitchcock

Ulrich Lücking

Hans Schick

Ursula Mönning

Amaury Ernesto Fernandez-Montalvan

Lars Wortmann

Lars Bärfacker

Volker Schulze

Ulf Bömer

Clara Christ

Hans-Georg Lerchen

Thomas Ernst Müller

Dirk Kosemund

Christoph Huwe

Joachim Kuhnke

Arwed Cleve

Detlev Sülzle

Helmut Sonnenschein

Franz Von Nussbaum

Julien Lefranc

Joanna Grudzinska-Goebel

Dieter Moosmayer

Uwe Eberspächer

Anja Richter

Cornelia Preuβe

Roman Hillig

Keith Graham

Stefan Kaulfuss

Detlef Stöckigt

Heinz Graubaum

Tobias Heinrich

Ulrike Rauh

Horst Irlbacher

Manfred Möwes

Steven Corsello

Cornelia Preusse

Christian Lechner

Steven M Corsello

Carsten Moeller

René Tempel

Jozsef Bálint

Amaury Ernesto Fernández-Montalván

Jérémie Xavier G Mortier

Alisha Caliman

Katarzyna Handing

Adelaide Clara Faria Alvares De Lemos

Uwe Eberspacher

Joszef Bálint

Florian Prinz

Ulrich Lucking

Hans (deceased) Schick

Jérémie Mortier

Hassan Y Harb

Ashley Eheim

Antje-Margret Wengner

Lars BÄRFACKER

The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1α and/or β) useful for the treatment of proliferative disorders.

3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

2-(morpholin-4-yl)-1,7-naphthyridines

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones

Compounds of formula (I) as defined herein and their use as pharmaceuticals. 

Benzyl substituted indazoles as BUB1 inhibitors

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.

17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

Compounds of formula (I), and their use as pharmaceuticals. 

Substituted benzylpyrazoles

Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

Heteroaryl substituted pyrazoles

Compounds of formula (I), processes for their preparation and their use as pharmaceuticals. 

The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-aryl derivatives of the formula I with progesterone-antagonizing action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception.

17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases

The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-benzylidene derivatives of the formula I, in which Y and X are each as defined in the claims and the description, to a process for preparation thereof and to the use thereof as medicaments.

17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases

Growing community of inventors

Berlin, Germany

Wilhelm Bone